NY-IFF
22.5.2023 12:56:26 CEST | Business Wire | Press release
IFF (NYSE:IFF) today released its 2022 Do More Good Report, which highlights performance and progress against goals set forth in the Do More Good Plan, the Company’s environmental, social, governance, plus sustainable solutions (or ESG+) strategy and roadmap that activates its purpose of applying science and creativity for a better world.
The Do More Good Report: IFF’s 2022 ESG+ Progress, describes the first full year of performance and progress as One IFF following the 2021 merger with DuPont’s Nutrition & Biosciences division. IFF will hold a live webcast to discuss the Company’s Do More Good Plan and goals, 2022 ESG+ results, and 2023 sustainability outlook on May 23, 2023, at 9:00 a.m. ET.
“When we launched our Do What Matters Most strategy in 2022, we committed to embedding ESG+ in all we do,” said Frank Clyburn, IFF CEO. “Our 2022 Do More Good Report illustrates the steps we’re taking to deliver on our commitments to address sustainable development imperatives. Our world-class R&D program and commitment to innovation fuels a pipeline of exciting sustainable solutions that are helping our customers reach their ESG goals and, in turn, responding to heightened consumer expectations on sustainability.”
The 2022 Do More Good Report is organized according to the four pillars of the Do More Good Plan, which reflect the areas where the Company can have the greatest positive impact in addressing the world’s most pressing sustainable development challenges: Sustainable Solutions; Climate & Planetary Health; Equity & Wellbeing; and Transparency & Accountability.
2022 performance highlights and achievements by IFF include:
- Recognized externally for ESG leadership, including being named to the Dow Jones Sustainability Indices for the third consecutive time, and maintaining the 2022 EcoVadis platinum sustainability rating, placing IFF among the top 1% of companies assessed;
- Enabled customers and consumers to save more CO2e than generated at IFF’s own manufacturing sites by accelerating the wider adoption of sustainable solutions in the marketplace, as documented by life cycle assessments;
- Named to the CDP Climate A list for the eighth consecutive year and completed its first virtual power purchase agreement, expected to cover approximately 30% of the total electricity needs of its European sites when it becomes operational at full capacity in 2024;
- Recertified as EDGE Move level globally for its commitment to gender parity, and included in the Bloomberg Gender-Equality Index for the second time;
- Introduced a Global Parental Leave Policy that grants a minimum of 16 weeks of 100% paid leave for a new IFF parent, regardless of gender identity or expression;
- Linked ESG performance metrics for reduction of greenhouse emissions and increases in company-wide gender representation to the Annual Incentive Plan Award for executive leaders, impacting 2022 variable compensation by 5%;
- Completed updates to its Code of Conduct training and certification campaign, achieving a 99.8% acknowledgment rate among employees.
To learn more, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.
Webcast
IFF will hold a live webcast to discuss the Company’s Do More Good Plan, 2022 key performance metrics, progress against 2030 goals and 2023 outlook on May 23, 2023 at 9:00 a.m. ET., where Mr. Clyburn will be joined by Michael DeVeau, Senior Vice President, Corporate Finance and Investor Relations; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Ralf Finzel, Chief Operations Officer; Deborah Borg, Chief Human Resources, Diversity, Equity & Inclusion and Communications Officer; and Jennifer Johnson, General Counsel and Corporate Secretary. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.
IFF invites investors, analysts and all IFF stakeholders to participate by phone by calling 1-404-975-4839 from the United States and toll-free from other locations by calling +1-833-470-1428. The access code for the conference call is 758853, and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, IFF will post a recorded version on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
